New horizons for stroke prevention: PROGRESS and HOPE.

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors block angiotensin I to angiotensin II conversion, impacting blood pressure and aldosterone.
• ACE inhibitors also affect bradykinin, a vasodepressor, and mitigate angiotensin II's hypertensive effects.
• Known benefits include improved vascular compliance and regression of cardiac hypertrophy, but stroke prevention data was limited.

Purpose of the Study:

• To review epidemiological evidence linking hypertension to stroke.
• To examine national guidelines for blood pressure control in stroke prevention.
• To analyze findings from the PROGRESS and HOPE trials regarding ACE inhibitors in stroke and cardiovascular disease prevention.

Main Methods:

• Review of epidemiological data on hypertension and stroke.
• Analysis of national blood pressure control guidelines.
• Evaluation of clinical trial data from PROGRESS and HOPE studies.

Main Results:

• Hypertension is a significant risk factor for stroke.
• ACE inhibitors demonstrated a crucial role in preventing stroke and cardiovascular events in the HOPE and PROGRESS trials.
• Findings suggest a redefinition of blood pressure management for high-risk populations.

Conclusions:

• ACE inhibitors are effective in preventing stroke and cardiovascular disease events.
• The results from the PROGRESS and HOPE trials support the use of ACE inhibitors for stroke prevention.
• Future management of blood pressure in high-risk individuals should consider the role of ACE inhibitors.